- Home
- CRGY vs VRDN Comparison
CRGY vs VRDN Comparison
Compare CRGY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRGY | VRDN |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRGY | VRDN |
|---|---|---|
| Price | $8.54 | $32.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $13.73 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 5.5M | 1.2M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $3,590,024,000.00 | $70,789,000.00 |
| Revenue This Year | $26.48 | $26,257.62 |
| Revenue Next Year | $26.79 | $4.54 |
| P/E Ratio | $83.10 | ★ N/A |
| Revenue Growth | 32.31 | ★ 23340.07 |
| 52 Week Low | $6.83 | $9.90 |
| 52 Week High | $16.56 | $34.29 |
Technical Indicators
Market Signals| Indicator | CRGY | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 52.45 |
| Support Level | $8.14 | $29.63 |
| Resistance Level | $8.75 | $34.29 |
| Average True Range (ATR) | 0.39 | 1.35 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 73.31 | 59.29 |
Price Performance
Historical ComparisonAbout CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).